Similarly, some gene alterations with matched therapies occurred at relatively higher frequencies in on-label cancer types, including alterations in PIK3CA (42.2% in on-label HR+/HER2- breast cancer vs. 10.6% in off-label cancers) and in EGFR (19.8% in on-label NSCLC vs. 0.1% in off-label cancers) (Figure 2D). This evidence concerns the gene ERBB2 and breast cancer.